<DOC>
	<DOCNO>NCT01806142</DOCNO>
	<brief_summary>Several line evidence indicate significant proportion cardiovascular disease ( CVD ) event attributable presence cluster metabolic abnormality perturbation , define metabolic syndrome . It estimate approximately 25 % North American adult population live metabolic syndrome . Recent study investigator group show overaccumulation atherogenic triglyceride-rich lipoprotein ( TRL ) see insulin-resistant patient partly due increase production rate intestinally derive apolipoprotein ( apo ) B-48-containing lipoprotein . This interest substantial evidence exists indicate elevated level intestinal lipoprotein associate increase CVD risk . In regard , evidence medium-chain triglyceride ( MCTs ) may beneficially modify lipoprotein metabolism hypertriglyceridemic patient . However , emphasize body grant proposal , specific impact MCTs intestinal lipoprotein secretion expression gene regulate intestinal lipid absorption chylomicron synthesis yet investigate human . The general objective propose research investigate mechanism MCTs beneficially modify intestinal lipoprotein metabolism patient metabolic syndrome . The primary hypothesis MCT supplementation decrease plasma level intestinal lipoprotein reduce secretion particle .</brief_summary>
	<brief_title>Effects Medium-Chain Triglycerides Chylomicron Secretion Expression Genes That Regulate Intestinal Lipid Metabolism Men With Dyslipidemia Associated With Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Men age 1860 year Waist circumference &gt; 102 cm HDLcholesterol &lt; 1.1 mmol/L Triglycerides &gt; 1.7 mmol/L Fasting blood glucose &gt; 6.1 mmol/L Normal blood pressure ( &lt; 130/85 ) Women Men &lt; 18 &gt; 60 year Smokers ( &gt; 1 cigarette/day ) Body weight variation &gt; 10 % last 6 month prior study baseline Subjects previous history cardiovascular disease Subjects type 2 diabetes Subjects monogenic dyslipidemia Subjects hypertension medication medication know affect lipoprotein metabolism integrity gastrointestinal mucosa Subjects endocrine gastrointestinal disorder History alcohol drug abuse within past 2 year Subjects situation condition , opinion investigator , may interfere optimal participation study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>